In STEP 8, serious adverse events (SAEs) occurred in 8% of semaglutide-treated patients, in 11% of liraglutide-treated patients, and in 7% of placebo-treated patients
Weight loss picks up as the dose increases and your body adapts to the medication
Passage of Molecules through the Wall of the Gastrointestinal Tract
The neuromodulatory role of GLP-1, influencing synaptic plasticity and neurotransmitter release, may alter the brains response to drug-related stimuli and reduce relapse risk [15, 43]
Glutamate and dopamine in schizophrenia: an update for the 21st century
Other serious risks include acute pancreatitis (reported as 0.23 cases per 100 patient-years), acute gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury (often secondary to dehydration from gastrointestinal effects), and hypersensitivity reactions